Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Major gene

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    221 result(s) found for: Major gene. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-006800-34 Sponsor Protocol Number: RONIN Start Date*: 2022-03-31
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: The Role of Negr1 In modulating Neuroplasticity in major depression
    Medical condition: patients with major depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004349-42 Sponsor Protocol Number: NP27936 Start Date*: 2012-07-16
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome.
    Medical condition: Fragile X Syndrome (FXS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2008-002857-18 Sponsor Protocol Number: H9P-MC-LNBI Start Date*: 2009-02-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment with LY2216684 in Adult Patients with Major Depressive Disorder
    Medical condition: Patients with Major Depressive Disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision® (DSM-IV-TR; APA 2004),
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-004780-34 Sponsor Protocol Number: A7571001 Start Date*: 2006-04-18
    Sponsor Name:Pfizer Ltd, Sandwich, UK
    Full Title: An eight-week, double-blind, group sequential design, placebo controlled trial to evaluate the safety and efficacy of the co-administration of sertraline and elzasonan (CP-448,187) in outpatients w...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025454 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003190-29 Sponsor Protocol Number: HMNC-101 Start Date*: 2012-01-30
    Sponsor Name:HolsboerMaschmeyer NeuroChemie (HMNC) GmbH
    Full Title: Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication according to the the ABCB1 Gene
    Medical condition: - Major Depression, single or recurrent, without psychotic features - Bipolar Disorders, currently depressed, without psychotic features
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    14.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    14.1 10037175 - Psychiatric disorders 10004940 Bipolar II disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014605-14 Sponsor Protocol Number: F1J-US-HMGR(a) Start Date*: 2010-01-08
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients with Major Depressive Disorder and Associated Painful Phy...
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    12.0 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-002069-30 Sponsor Protocol Number: 13069 Start Date*: 2008-12-05
    Sponsor Name:Bayer Vital GmbH
    Full Title: A randomized, double-blind, single centre, placebo-controlled pilot study to assess on a molecular level the influence of a 5 % dexpanthenol ointment in subjects with previously injured skin by inv...
    Medical condition: Biopsy wounds on healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002517-36 Sponsor Protocol Number: CA180-015 Start Date*: 2004-12-27
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib...
    Medical condition: Lympohid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) FI (Completed) GB (Completed) DK (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002516-28 Sponsor Protocol Number: CA180-006 Start Date*: 2004-12-27
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate Revised Protocol 01: Incorporates Amendment 03 and Admi...
    Medical condition: Myeloid Blast Phase Chronic Myeloid Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) FI (Completed) GB (Completed) DK (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004182-26 Sponsor Protocol Number: ELIA Start Date*: 2009-02-02
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression
    Medical condition: 30-40% of depressed patients do not respond to the first course of drug treatment chosen. Over 50% of nonresponders to the first treatment also do not respond to a second, different treatment . Of ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002515-89 Sponsor Protocol Number: CA180-005 Start Date*: 2004-12-27
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate Revised Protocol 01: Incorporates Amendment 03 and Admini...
    Medical condition: Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) FI (Completed) GB (Completed) IT (Completed) DE (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002255-37 Sponsor Protocol Number: MGT-RPGR-022 Start Date*: 2022-05-26
    Sponsor Name:MeiraGTx UK II Limited
    Full Title: Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) NL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) DE (Prematurely Ended) IT (Trial now transitioned) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2010-021044-17 Sponsor Protocol Number: CLOCK_depression Start Date*: 2010-08-11
    Sponsor Name:Medizinische Universität Wien
    Full Title: The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study.
    Medical condition: Major depressive disorder (MDD), Seasonal affective disorder (subtype of MDD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012378 Depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000601-77 Sponsor Protocol Number: 5051-201 Start Date*: 2019-12-11
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, then Dose Expansion, in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IE (Prematurely Ended) ES (Temporarily Halted) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Restarted) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000695-42 Sponsor Protocol Number: HGB-205 Start Date*: 2012-12-31
    Sponsor Name:bluebird bio, Inc.
    Full Title: A Phase I/II Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem...
    Medical condition: Severe sickle cell anemia and transfusion-dependent beta-thalassemia major. This study will enroll patients who are eligible for an allogeneic hematopoietic stem cell transplant (HSCT) but do not...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10055579 Sickle-cell beta thalassemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001856-51 Sponsor Protocol Number: 12.007 Start Date*: 2014-08-26
    Sponsor Name:Aleksander Krag
    Full Title: Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial
    Medical condition: Liver fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10016648 Fibrosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004442-11 Sponsor Protocol Number: JAZ-01 Start Date*: 2020-12-01
    Sponsor Name:Zealand University Hospital
    Full Title: The effect of Melatonin in patients with Low Anterior Resection Syndrome
    Medical condition: Low anterior resection syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10080023 Low anterior resection syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002970-36 Sponsor Protocol Number: 54508 Start Date*: 2016-06-06
    Sponsor Name:Maastricht University Medical Center
    Full Title: Human intestinal ischemia and reperfusion
    Medical condition: The participants enrolled in this study will all undergo major upper abdominal surgery (i.e. mostly Pylorus Preserving Pancreatico Duodenectomy or whipple procedure) mostly for pancreatic cancer, p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002245-11 Sponsor Protocol Number: LTF-303 Start Date*: 2013-11-12
    Sponsor Name:bluebird bio, Inc.
    Full Title: Long-term Follow-up of Subjects Treated with Ex Vivo Gene Therapy using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector
    Medical condition: Subjects treated with gene therapy drug products in a bluebird bio-sponsored or associated clinical study will be invited to participate in this long-term follow-up study to monitor the safety and ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10055579 Sickle-cell beta thalassemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022388-37 Sponsor Protocol Number: TUD-RELA02-048 Start Date*: 2011-09-23
    Sponsor Name:Technische Universität Dresden
    Full Title: Treatment of patients with MDS or AML with an impending hematological relapse with Azacitidin (Vidaza)
    Medical condition: Patients with AML or MDS >= 18 years of age after conventional chemotherapy or stem cell transplantation with significant residual disease or an increase of MRD (e.g. t(6,9), NPM1 or CD34+ or CD117...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10060557 Acute myelocytic leukemia LLT
    20.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 25 13:16:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA